DEFJ to Become Controlling Shareholder After Waiving Ownership Cap

summarizeSummary

DEFJ waived its ownership cap and will convert preferred stock to become Transcode's 83.9% controlling shareholder, consolidating control amid the company's financial distress.

check_boxKey Events · Ownership and Investor Activity · RNAZ

• Ownership Cap Waived

  DEFJ waived the 9.99% beneficial ownership limitation on its Series A and Series B Preferred Stock, effective 60 days from July 27, 2026, allowing full conversion into common shares.

• Controlling Stake Emerges

  Upon conversion, DEFJ will hold 14,134,481 shares, or 83.9% of outstanding common stock, based on 3,017,306 shares outstanding as of July 23, 2026, making it the controlling shareholder.

• Extreme Dilution for Public Holders

  The conversion will increase the fully diluted share count from 3.0 million to approximately 16.8 million shares, diluting existing public shareholders to a small minority.

• No New Capital Inflow

  The conversion does not provide any new cash to Transcode, which had only enough cash to operate into Q3 2025 per its last quarterly filing and faces a Nasdaq delisting for insufficient equity.

auto_awesomeAnalysis · RNAZ · Life Sciences

DEFJ, an affiliate of CK Life Sciences, has waived the 9.99% beneficial ownership limitation on its preferred stock, clearing the way to convert all Series A and Series B shares into common stock. Once effective in 60 days, DEFJ will hold 83.9% of Transcode's outstanding shares, becoming the controlling shareholder. This follows shareholder approval of the conversion in July and comes as the company faces a Nasdaq delisting threat and a going concern warning. The move consolidates control but does not provide new capital; existing shareholders face extreme dilution, with DEFJ's stake dwarfing the current public float.